Search Results - "Karnon, Jon"

Refine Results
  1. 1
  2. 2

    Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial by Schultz, Tim, Thomas, Anne, Georgiou, Paul, Juaton, Mahasen, Simon, Lorraine, Cusack, Lynette, Naidoo, Kerisha, Webb, Kevin, Karnon, Jon

    Published in International journal of integrated care (08-08-2019)
    “…We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study…”
    Get full text
    Journal Article
  3. 3

    An equity-effectiveness framework linking health programs and healthy life expectancy by Banham, David, Lynch, John, Karnon, Jon

    “…South Australia's Strategic Plan includes a target to improve the population's healthy life expectancy. A common question among health policy and service…”
    Get more information
    Journal Article
  4. 4

    The Value of Value of Information: Best Informing Research Design and Prioritization Using Current Methods by Eckermann, Simon, Karnon, Jon, Willan, Andrew R.

    Published in PharmacoEconomics (01-01-2010)
    “…Value of information (VOI) methods have been proposed as a systematic approach to inform optimal research design and prioritization. Four related questions…”
    Get full text
    Journal Article
  5. 5

    022 Piloting home infusions of natalizumab: a randomised crossover trial by Schultz, Tim, Thomas, Anne, Georgiou, Paul, Juaton, Mahasen, Simon, Lorraine, Cusack, Lynette, Naidoo, Kerisha, Webb, Kevin, Karnon, Jon, Ravindran, Janakan

    “…IntroductionFor people with multiple sclerosis, monthly infusions at specialist clinics are time consuming, potentially costly and restrictive. Conversely,…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9

    Supporting surgeons in patient-centred complex decision-making: a qualitative analysis of the impact of a perioperative physician clinic by Pham, Clarabelle T, Gibb, Catherine L, Fitridge, Robert A, Karnon, Jon, Hoon, Elizabeth

    Published in BMJ open (23-12-2019)
    “…ObjectivePatients with comorbidities can be referred to a physician-led high-risk clinic for medical optimisation prior to elective surgery at the discretion…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12

    The Value of Value of Information by Eckermann, Simon, Karnon, Jon, Willan, Andrew R

    Published in PharmacoEconomics (01-09-2010)
    “…Value of information (VOI) methods have been proposed as a systematic approach to inform optimal research design and prioritization. Four related questions…”
    Get full text
    Journal Article
  13. 13

    Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab by Delea, Thomas E., Tappenden, Paul, Sofrygin, Oleg, Browning, Dominy, Amonkar, Mayur M., Karnon, Jon, Walker, Mel D., Cameron, David

    Published in The European journal of health economics (01-10-2012)
    “…Background In a phase III trial of women with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab, an anthracycline, and taxanes…”
    Get full text
    Journal Article
  14. 14

    Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide by Liubao, Peng, Xiaomin, Wan, Chongqing, Tan, Karnon, Jon, Gannong, Chen, Jianhe, Li, Wei, Cui, Xia, Luo, Junhua, Cao

    Published in PharmacoEconomics (01-01-2009)
    “…Background: An oncology trial compared four cycles of doxorubicin/cyclophosphamide (AC) with four cycles of docetaxel/cyclophosphamide (TC) in operable breast…”
    Get full text
    Journal Article
  15. 15

    Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer by EL OUAGARI, Khalid, KARNON, Jon, DELEA, Thomas, TALBOT, Willena, BRANDMAN, Jane

    Published in Breast cancer research and treatment (01-01-2007)
    “…Adjuvant tamoxifen therapy for 5 years reduces recurrence in hormone receptor positive, post-menopausal women with early breast cancer, but offers no advantage…”
    Get full text
    Journal Article
  16. 16

    Maximising recruitment and retention of general practices in clinical trials: a case study by Dormandy, Elizabeth, Kavalier, Fred, Logan, Jane, Harris, Hilary, Ishmael, Nola, Marteau, Theresa M

    Published in British journal of general practice (01-11-2008)
    “…There is limited evidence regarding the factors that facilitate recruitment and retention of general practices in clinical trials. It is therefore pertinent to…”
    Get full text
    Journal Article
  17. 17

    A stochastic economic evaluation of Letrozole versus tamoxifen as a first-line hormonal therapy: For advanced breast cancer in postmenopausal patients by KARNON, Jon, JONES, Trefor

    Published in PharmacoEconomics (2003)
    “…Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced…”
    Get full text
    Journal Article
  18. 18

    Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer by Delea, Thomas E, Karnon, Jon, Sofrygin, Oleg, Thomas, Simu K, Papo, Natalie L, Barghout, Victoria

    Published in Clinical breast cancer (01-06-2007)
    “…Abstract Background In Breast International Group (BIG) 1–98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK by Karnon, Jon, Brennan, Alan, Pandor, Abdullah, Fowkes, Gerry, Lee, Amanda, Gray, David, Coshall, Catherine, Nicholls, Charles, Akehurst, Ron

    Published in Current medical research and opinion (01-01-2005)
    “…ABSTRACT Objective: To assess the long term cost effectiveness of clopidogrel monotherapy compared with acetylsalicylic acid (aspirin; ASA) monotherapy in…”
    Get full text
    Journal Article